• Unsuccessful brain cancer drugs U.S. 1998-2014 | Statistic

Health & Pharmaceuticals ›
Pharmaceutical Products & Market ›
Unsuccessful developing brain cancer drugs in the U.S. 1998-2014

Premium
Number of unsuccessful brain cancer drugs in development in the United States from 1998 to 2014

Loading statistic...

© Statista 2017

Show further information

Complete Source Details

About This Statistic

This statistic shows the number of unsuccessful brain cancer drugs in development in the United States from 1998 to 2014. In 2011, there were six unsuccessfully developed brain cancer drugs. Since 1998, there have been 75 total medicines being developed for brain cancer that were discontinued, suspended, or had no development reported and 3 approved medications.

Special Functions

Download as ...

Options

Number of cancer drugs in development in the U.S. 2005-2015

Number of cancer drugs in development in the U.S. 2005-2015

Medicines in development for selected cancer types in the U.S. 2015

Medicines in development for selected cancer types in the U.S. 2015

Top cancer drugs based on revenue worldwide 2015

Top cancer drugs based on revenue worldwide 2015

Medicines in development for cancer in the United States 2015

Medicines in development for cancer in the United States 2015

Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

Top cancer drugs paid by Medicare Part B by sales price per dosage 2014

Top cancer drugs paid by Medicare Part B by sales price per dosage 2014

Statista Accounts: Access All Statistics. Starting from $588 / Year

Prices & Access

Statistics on "Generics and biosimilars"

The most important statistics

Global pharmaceutical market revenue from 2008 to 2015 (in billion U.S. dollars)*Global pharmaceutical market revenue 2008-2015
Worldwide total generic prescription drug revenue from 2008 to 2022 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2008-2022
Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2008 to 2022Global generic prescription drug revenues as share of prescribed revenue 2008-2022
Worldwide total prescription drug revenue at risk from patent expiration from 2008 to 2022 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2008-2022

The most important statistics

Top 20 generic pharmaceutical companies worldwide in 2015, by revenue (in million U.S. dollars)Top global generic pharmaceutical companies 2015, by revenue
Top 20 generic pharmaceutical companies worldwide as of 2016, by enterprise value (in million U.S. dollars)Top global generic pharmaceutical companies, by enterprise value 2016
Value share of top 10 generic pharmaceutical companies worldwide as of 2016*Top global generic pharmaceutical company value share 2016
Generic revenues of Teva Pharmaceutical Industries from 2014 to 2016, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2014-2016
Pfizer's revenue in 2014 and 2016, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2016
Top 10 generic drug manufacturers worldwide based on market share in 2014*Leading global generic drug manufacturers by market share 2014

The most important statistics

Brand and generic prescription medication revenue in the U.S. from 2006 to 2016 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2016
Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016U.S. brand and generic prescription drug revenue 2005-2016
Change in branded and generic medication spending in the United States from 2009 to 2015 (in billion U.S. dollars)Spending change on branded and generic medicines in the U.S. 2009-2015
Top 20 generic pharmaceutical companies with a U.S. operating presence as of 2016, by enterprise value (in million U.S. dollars)Enterprise value of generic pharmaceutical companies with a U.S. presence 2016
Top 20 generic pharmaceutical companies with a U.S. operating presence in 2015, by revenue (in million U.S. dollars)Revenue of top generic pharma companies with U.S. presence 2015
Top 20 U.S. pharma products by dispensed prescriptions in 2016 (in millions)Top U.S. pharma products by prescriptions 2016
Top U.S. generic pharmaceutical industry acquisitions in 2015 (in billion U.S. dollars)U.S. generic pharmaceutical industry top acquisitions 2015

The most important statistics

Major generic introductions of branded drugs in the U.S. in 2016, by sales (in million US dollars)*Estimated sales of major generic introductions in U.S. 2016
Leading drugs going off patent in the U.S. in 2017, by revenue (in million U.S. dollars)*Biggest selling drugs with patent at threat in the U.S. in 2017, by revenue
Share of company sales of leading drugs going off patent in the U.S. in 2017*Share of company sales of biggest selling drugs going generic in the U.S. in 2017
Reduction in value due to expiring patents in the United States from 2016 to 2019 (in billion U.S. dollars)*Value of expiring patents in U.S. 2016-2019
Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
Monthly price reduction of generic drugs after loss of exclusivity in the United States as of 2015Price reduction of genric drugs after loss of exclusivity in the U.S. 2015

The most important statistics

Savings through generic drug usage in the United States from 2005 to 2015 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2005-2015
Cost savings through generics in the United States in 2015, by therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by therapy 2015
Savings through generic drug usage in the United States in 2015, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2015
Savings through generic drug usage in the United States in 2015, by payor (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payor 2015
Savings through generic drug usage in Medicaid during 2015, by state (in million U.S. dollars)Medicaid program savings through generic drug usage by U.S. state 2015
Savings through generic drug usage in Medicare during 2015, by state (in million U.S. dollars)*Medicare savings through generic drug usage in the U.S. by state 2015
Top generic drugs based on savings in the United States in 2015 (in million U.S. dollars)Total savings of top generic drugs in the U.S. in 2015

The most important statistics

Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*Major biologics to lose patent protection 2015-2020 by EU5 and U.S. revenue
Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
Global market forecast for oncologics and supportive care biosimilars in 2015 and 2020 (in billion U.S. dollars)Global market forecast of oncologics and supportive care biosimilars 2020
Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
Example of physician office payment for biosimilars in Medicare Part B as of 2016 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2016
Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015First biosimilar marketing initiatives by MCOs in U.S. 2015
Knowledge about biosimilars among consumers in the United States as of 2015U.S. consumers knowledge about biosimilars 2015

Statista for Your Company: The Research and Analysis Tool

Product Film
Statistics
Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics. 93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Google

Samsung

Unilever

Procter and Gamble

Adobe

Telekom

PayPal

Otto

Further Content: Statistics, Studies, and Topic Pages

Statistics

Topics

Studies

Our Business Solutions: Save Time and Money

only

$588^*

per year

Your advantages

Full access to all our statistics
Download as XLS, PDF & PNG
Relevant data: complete source information

All functions of our platform illustrated face-to-face

Learn how Statista supports your company
Extensive tour across the whole portal
Personal guidance by our support team

Request webinar

The knowledge database for your company

All functions of the Premium Account
Access to dossiers, forecasts and studies
Access to our international database
Publishing rights and other exclusive functions

* All products require an annual contract.
Prices do not include sales tax
(New York residents only).